Showing results (841-850 of 2,488) with videos related to
Sort By:
Pageof 249
Expert Review of Vaccines|December 25, 2024
Immunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged ≥18 years: interim results of a randomized, active-controlled, double-blinded, phase 3 trialBei-Fang Yang, Jing Jin, Xi-Ran He, et al.Expert Review of Vaccines|March 26, 2025
Protection and waning of vaccine-induced, natural and hybrid immunity to SARS-CoV-2 in Hong KongJialiang Jiang, Kwok Fai Lam, Eric Ho Yin Lau, et al.Expert Review of Vaccines|April 3, 2025
Economic analysis of 15-valent and 20-valent pneumococcal conjugate vaccines among older adults in Ontario, CanadaGebremedhin B Gebretekle, Ryan O'Reilly, Stephen Mac, et al.Expert Review of Vaccines|March 6, 2025
Progress and challenges in Nipah vaccine development and licensure for epidemic preparedness and responseSol Kim, Hyolim Kang, Laura Skrip, et al.Expert Review of Vaccines|December 13, 2024
Readiness assessment for cervical cancer elimination and prevention of human papillomavirus (HPV)-related cancers in Europe - are we winning the RACE?Eugenia Karamousouli, Ugne Sabale, Stefano Valente, et al.Expert Review of Vaccines|December 16, 2024
Knowledge, attitudes, and perceptions towards pneumococcal vaccines among adults in the United StatesSalini Mohanty, Jui-Hua Tsai, Ning Ning, et al.Expert Review of Vaccines|November 13, 2024
Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86/JN.1 period among older adults in seven European countries: A VEBIS-EHR network studyBaltazar Nunes, James Humphreys, Nathalie Nicolay, et al.Expert Review of Vaccines|October 22, 2024
Indirect protection in adults ≥18 years of age from pediatric pneumococcal vaccination: a reviewElmira Flem, Celine Mouawad, Arto A Palmu, et al.Expert Review of Vaccines|September 11, 2024
Vaccination strategies for patients under monoclonal antibody and other biological treatments: an updated comprehensive review based on EMA authorisations to January 2024Mario Rivera-Izquierdo, Arturo Morales-Portillo, Inmaculada Guerrero-Fernández de Alba, et al.Expert Review of Vaccines|February 7, 2025
Immunogenicity and safety of a live attenuated varicella vaccine in healthy subjects aged between 13 to 55 years: a double-blind, randomized, active-controlled phase III clinical trial in ChinaYang Zhang, Shiyuan Wang, Guifan Li, et al.Pageof 249